Nicholas R Latimer
Overview
Explore the profile of Nicholas R Latimer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibbons C, Latimer N
Value Health
. 2024 Dec;
28(3):406-414.
PMID: 39725010
Objectives: Between 2015 and 2017, 41% of National Institute for Health and Care Excellence (NICE) cancer single-technology appraisal (STA) decisions relied upon immature survival data. This occurs when clinical trials...
2.
Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, et al.
Pharmacoeconomics
. 2024 Sep;
42(12):1395-1412.
PMID: 39302594
Background And Objective: Accurately extrapolating survival beyond trial follow-up is essential in a health technology assessment where model choice often substantially impacts estimates of clinical and cost effectiveness. Evidence suggests...
3.
Bullement A, Edmondson-Jones M, Guyot P, Welton N, Baio G, Stevenson M, et al.
Pharmacoeconomics
. 2024 Aug;
42(12):1317-1327.
PMID: 39207595
Survival extrapolation often plays an important role in health technology assessment (HTA), and there are a range of different approaches available. Approaches that can leverage external evidence (i.e. data or...
4.
Taylor K, Latimer N, Douglas T, Hatswell A, Ho S, Okorogheye G, et al.
Pharmacoeconomics
. 2024 Aug;
42(11):1181-1196.
PMID: 39177877
Treatment effect waning (TEW) refers to the attenuation of treatment effects over time. Assumptions of a sustained immuno-oncologic treatment effect have been a source of contention in health technology assessment...
5.
Latimer N, Rutherford M
Pharmacoeconomics
. 2024 Jul;
42(10):1073-1090.
PMID: 38967908
There is increasing interest in the use of cure modelling to inform health technology assessment (HTA) due to the development of new treatments that appear to offer the potential for...
6.
Chang J, Chilcott J, Latimer N
Pharmacoeconomics
. 2024 Apr;
42(5):487-506.
PMID: 38558212
With an ever-increasing number of treatment options, the assessment of treatment sequences has become crucial in health technology assessment (HTA). This review systematically explores the multifaceted challenges inherent in evaluating...
7.
Latimer N, Dewdney A, Campioni M
BMC Med Res Methodol
. 2024 Jan;
24(1):17.
PMID: 38253996
Background: Treatment switching in randomised controlled trials (RCTs) is a problem for health technology assessment when substantial proportions of patients switch onto effective treatments that would not be available in...
8.
Jennings A, Rutherford M, Latimer N, Sweeting M, Lambert P
Value Health
. 2023 Dec;
27(3):347-355.
PMID: 38154594
Objectives: A long-term, constant, protective treatment effect is a strong assumption when extrapolating survival beyond clinical trial follow-up; hence, sensitivity to treatment effect waning is commonly assessed for economic evaluations....
9.
Lee S, Lambert P, Sweeting M, Latimer N, Rutherford M
Value Health
. 2023 Oct;
27(1):51-60.
PMID: 37858887
Objectives: Parametric models are used to estimate the lifetime benefit of an intervention beyond the range of trial follow-up. Recent recommendations have suggested more flexible survival approaches and the use...
10.
Sweeting M, Rutherford M, Jackson D, Lee S, Latimer N, Hettle R, et al.
Med Decis Making
. 2023 Jul;
43(6):737-748.
PMID: 37448102
Background: Different parametric survival models can lead to widely discordant extrapolations and decision uncertainty in cost-effectiveness analyses. The use of excess hazard (EH) methods, which incorporate general population mortality data,...